SARC is an advocate for sarcoma medical research and clinical trials. We facilitate dialogue and collaboration among sarcoma researchers and clinicians, develop and sponsor clinical trials, administer research grants and funding for clinical trials, and act as a primary resource for those treating sarcoma.

SARC is formalizing its current research structure by establishing a consortium of institutional partners via a new, uniform Master Collaboration Agreement. Membership to the SARC Consortium is by invitation only.

About the Master CollaboratION Agreement

The SARC Master Collaboration Agreement (MCA) governs the collaborative relationship and sets forth the primary terms for the conduct of research. The agreement is analogous to other collaborative research agreements to which many of the leading research institutions are already a party, such as agreements with the Alliance for Clinical Trials in Oncology and the National Clinical Trials Network. SARC closely collaborated with a subset of its institutional and academic partners to prepare and arrive at the final MCA. The agreement will streamline collaborations and contracting processes in service of our shared mission to advance research to the benefit of patients globally.


To qualify, institutions must: 

  • Execute the SARC Master Collaboration Agreement
  • Have sarcoma expertise at a multidisciplinary level (i.e. surgical oncology, medical oncology, pediatric oncology, orthopaedic oncology, radiation therapy, pathology and radiology)
  • Have a significant sarcoma program that sees at least 70 new cases of sarcoma annually
  • Demonstrate experience in conducting sarcoma clinical research and/or laboratory translational research

As a SARC Consortium Member we encourage your institution’s representatives to:

  • Actively collaborate in the exchange of ideas to advance the science of sarcomas
  • Pool intellectual and patient resources to accelerate the cure for sarcoma by conducting coordinated, multi-center translational research projects
  • Participate in discussions, collaborations, and SARC committee meetings including:
    • SARC Consortium Membership Committee
    • Clinical Trialist Group
    • Multidisciplinary Tumor Board
    • SARC elective working groups such as the Executive Scientific Steering Committee, Discovery/Translational Committee, Concept Review Committee, and Clinical Trialist Development Committee
  • Submit initial concepts or fully realized studies to the Concept Review Committee for SARC to partner, support, and/or facilitate
  • Participate in SARC’s sponsored clinical trials
  • Attend SARC meetings and events
  • Network and share information about your organization and the Sarcoma Centers Registry

SARC Consortium Members will be highlighted within the new Sarcoma Centers Registry listing and map.

For more information about membership, contact SARC President & CEO Steven Young.

Back to top